System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Hans Prenen is an expert in Oncology at Antwerp University Hospital (Belgium). As of October 2026, ScienceLeadR ranks Hans Prenen in the top 1% of experts worldwide for Intestinal Neoplasms, Rectal Diseases and Gastrointestinal Neoplasms. Hans Prenen has authored 315 publications, the most recent in 2026, and is an investigator in 67 clinical trials, 30 of them ongoing. SLR score: 2,098 (community average: 125). How the SLR is computed.

LeadR Profile

Hans Prenen Antwerp University Hospital Belgium
2 098 ScienceLeadR Reputation 2098

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hematology - Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026
Source: PubMed

Antwerp University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 315

Citations

Citations: 16 786 1st author: 28 Last author: 33 Unique author: 0

Main journals

Ann Oncol 41
J Clin Oncol 34
Cancer Res 11
Clin Cancer Res 10
Ann Gastroenterol 8

Best Journals

Ann Oncol 30
J Clin Oncol 23
Lancet Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Comparative characterization of OncoPro™ and Wnt-based media reveals distinct phenotypic and pharmacologic states in patient-derived tumor organoids.
PMID 42934735 — cells, tissue adhesions, genes, pharmaceutical preparations, neoplasms, organoids, colorectal neoplasms		Exp Hematol Oncol20260
Attitudes of cancer patients toward ctDNA-based liquid biopsy for follow-up.
PMID 42905048 — mental recall, neoplasms, biopsy, therapeutics, liquid biopsy		Mol Oncol20260
Real-world utilization of pembrolizumab dosing schedules in Belgium: a multi-center retrospective study using a common data model and natural language processing.
PMID 42905135 — natural language processing, language, retrospective studies, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, electronic health records, privacy, immune checkpoint inhibitors, therapeutics		J Comp Eff Res20260
Geneo study: Comprehensive genomic profiling versus limited local reimbursed NGS panels within the belgian Precision initiative.
PMID 42773586 — neoplasms, therapeutics		Eur J Cancer20260
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
PMID 42716074 — leucovorin, disease-free survival, docetaxel, adenocarcinoma, oxaliplatin, fluorouracil, therapeutics		Lancet Top journal20262

Clinical Studies 67

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 1 26
Phase 2 14
Phase 3 13
Phase 1/Phase 2 8
N/A 5
Phase 2/Phase 3 1

By status:

Recruiting 23
Completed 19
Active not recruiting 10
Terminated 10
Not yet recruiting 2
Unknown 2
Suspended 1

By type:

Interventional 65
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 5
multicentric5to9 4
multicentricup10 55

Main Topics

Ongoing Clinical Trials

30 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
2025-521707-48-00 — neoplasms		Phase 1Recruiting2025
AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability High Mismatch Repair Deficient Solid Tumors
2025-524056-63-00 — dna mismatch repair, microsatellite repeats, neoplasms, therapeutics, microsatellite instability, mmr-deficient, msi-h		Phase 1Recruiting2026
A Study to Evaluate the Safety Pharmacokinetics and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
2023-504709-35-00 — safety, neoplasms, pharmacokinetics		Phase 1Active not recruiting2023
A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus
2024-519787-40-00 — stomach, esophagus, esophagogastric junction, neoplasms, adenocarcinoma, work, therapeutics, esophageal neoplasms, capecitabine, stomach neoplasms		Phase 3Not yet recruiting2026
Beamion BCGC 1 A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2 cancer that has spread
2023-509566-38-00 — breast neoplasms, esophagogastric junction, neoplasms, adenocarcinoma, breast, therapeutics, colorectal neoplasms, capecitabine, trastuzumab		Phase 1/Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS